GZMK and colorectal carcinoma: However, the extracellular GzmK also promotes the release of soluble vascular endothelial growth factor receptor 1 (sVEGFR1) from endothelial cells independent of PAR1 activation to inhibit angiogenesis in CRC, indicating that targeting the GrK–sVEGFR1–angiogenesis axis may serve as a novel approach to target CRC [333].